人参多糖注射液联合TP方案对晚期非小细胞肺癌患者Th1/Th2免疫平衡和血清肿瘤标志物的影响  

Effects of Ginseng Polysaccharide Injection Combined with TP Regimen on Th1/Th2 Immune Balance and Serum Tumor Markers in Patients with Advanced Non-Small Cell Lung Cancer

作　　者：王敏 孔德军 杨莉 叶璐 母丹 WANG Min;KONG De-jun;YANG Li;YE Lu;MU Dan(Department of Oncology,The Second Affiliated Hospital of Chengdu Medical College•Nuclear Industry 416 Hospital,Chengdu,Sichuan,610051,China)

机构地区：[1]成都医学院第二附属医院·核工业四一六医院肿瘤科,四川成都610051

出　　处：《现代生物医学进展》2022年第7期1352-1356,共5页Progress in Modern Biomedicine

基　　金：四川省卫生和计划生育委员会科研项目(1602926)。

摘　　要：目的:探讨人参多糖注射液联合多西他赛和顺铂(TP方案)治疗晚期非小细胞肺癌(NSCLC)的疗效及对患者辅助性T细胞(Th)1/Th2免疫平衡和血清肿瘤标志物的影响。方法:选取我院2019年3月~2021年2月收治的80例晚期NSCLC患者。按随机数字表法分为对照组(TP方案治疗,40例)和观察组(人参多糖注射液联合TP方案治疗,40例)。对比两组疗效、血清肿瘤标志物、Th1/Th2免疫平衡指标、生存质量和不良反应发生率。结果:观察组的客观缓解率、疾病控制率分别为55.00%、85.00%,分别高于对照组的32.50%、57.50%,差异有统计学意义(P<0.05)。两组治疗4个疗程后肺癌患者生存质量量表(FACT-L)各领域评分均较治疗前升高,且观察组高于对照组(P<0.05)。两组治疗4个疗程后血清肿瘤标志物糖类抗原19-9(CA19-9)、细胞角蛋-19片段(CYFRA21-1)、癌胚抗原(CEA)水平下降,且观察组低于对照组(P<0.05)。两组治疗4个疗程后血清γ-干扰素(INF-γ)、白介素-2(IL-2)水平升高,且观察组高于对照组(P<0.05)。两组治疗4个疗程后血清白介素-4(IL-4)、白介素-5(IL-5)水平降低,且观察组低于对照组(P<0.05)。两组不良反应发生率对比无统计学差异(P>0.05)。结论:晚期NSCLC在TP化疗基础上结合人参多糖注射液治疗,可更好的降低血清肿瘤标志物水平,控制疾病进展,同时还可调节Th1/Th2免疫平衡,促进患者生存质量改善。Objective: To investigate the efficacy of ginseng polysaccharide injection combined with docetaxel and cisplatin(TP Regimen) in the treatment of advanced non-small cell lung cancer and its effects on helper T cell(Th) 1/Th2 immune balance and serum tumor markers of patients. Methods: 80 patients with advanced NSCLC who were treated in our hospital from March 2019 to February2021 were selected. According to the random number table method, they were randomly divided into control group(treated with TP Regimen, 40 cases) and observation group(treated with ginseng polysaccharide injection combined with TP Regimen, 40 cases). The efficacy, serum tumor markers, Th1/Th2 immune balance index, quality of life and incidence of adverse reactions were compared between the two groups. Results: The objective remission rate and disease control rate of the observation group were 55.00% and 85.00%respectively, which were higher than 32.50% and 57.50% of the control group, the difference was statistically significant(P<0.05). 4courses after treatment, the scores of each field of quality of life scale(FACT-L) of lung cancer patients in the two groups were higher than those before treatment, and the scores of the observation group were higher than those of the control group(P<0.05). 4 courses after treatment, the levels of tumor markers carbohydrate antigen 19-9(CA19-9), cytokeratin-19 fragment(CYFRA21-1) and carcinoembryonic antigen(CEA)) in the two groups decreased, and the observation group was lower than the control group(P<0.05). 4courses after treatment, the level of serum γ-interferon(INF-γ) and interleukin-2(IL-2) in the two groups were increased, and the observation group was higher than the control group(P<0.05). 4 courses after treatment, the levels of interleukin-4(IL-4) and interleukin-5(IL-5) in the two groups were decreased, and the observation group was lower than the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: The treat

关 键 词：人参多糖注射液 TP方案 晚期非小细胞肺癌 Th1/Th2免疫平衡 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]